Glioblastoma Multiforme, Diagnosis and Treatment; Recent Literature Review

Curr Med Chem. 2017;24(27):3002-3009. doi: 10.2174/0929867324666170516123206.


Background: Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor, with an incidence of 3.19 cases per 100,000 person years and remarkably poor prognosis showing a 5-year survival rate of 4-5%, and only a 26-33% survival rate at 2 years in clinical trials.

Objective: In this paper, we review the different types of treatment modalities based on the relevant databases. Methods of diagnosis will be described briefly.

Method: Systemic compilation of the relevant literature.

Results & conclusion: Today's treatments cannot cure GBM patients but only extend their overall survival. The use of chemoradiation, immunotherapy, and radio sensitizers as an adjuvant therapy cannot reduce the high rates of recurrence within a few months after treatment. Radiotherapy will remain the backbone of the treatment but new treatment modalities must be developed.

Keywords: Biologic agent; chemotherapy; glioblastoma multiforme; immunotherapy; radiation therapy; vaccination..

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Antineoplastic Agents, Alkylating / therapeutic use
  • Brain Neoplasms / diagnosis*
  • Brain Neoplasms / mortality
  • Brain Neoplasms / therapy
  • Cell- and Tissue-Based Therapy
  • Combined Modality Therapy
  • Dendritic Cells / immunology
  • Dendritic Cells / metabolism
  • Glioblastoma / diagnosis*
  • Glioblastoma / mortality
  • Glioblastoma / therapy
  • Humans
  • Immunotherapy
  • Poliovirus / genetics
  • Poliovirus / immunology
  • Poliovirus / metabolism


  • Antibodies, Monoclonal
  • Antineoplastic Agents, Alkylating